The WHO guidelines for Dolutegravir use have shaped global HIV treatment strategies, making effective therapy more accessible worldwide.

WHO Recommendations:
The World Health Organization recommends Dolutegravir-based regimens as preferred first-line and second-line treatment for all populations.

First-Line Treatment:
WHO recommends Dolutegravir 50mg once daily plus two NRTIs (tenofovir disoproxil fumarate or tenofovir alafenamide plus lamivudine or emtricitabine).

Second-Line Treatment:
For patients failing first-line therapy, Dolutegravir-based regimens are recommended with appropriate NRTI backbone selection based on resistance testing.

Pregnant Women:
After careful evaluation of benefits and risks, WHO recommends Dolutegravir for pregnant women with appropriate counseling about potential risks.

Children and Adolescents:
Dolutegravir is recommended for children weighing at least 6 kg, using weight-based dosing with dispersible tablets for younger children.

Implementation Considerations:
WHO provides guidance on transitioning patients from older regimens to Dolutegravir-based therapy, including monitoring and safety considerations.

Public Health Impact:
Dolutegravir adoption has improved treatment outcomes globally, with higher rates of viral suppression and lower rates of treatment failure.

Access and Affordability:
Generic Dolutegravir has made high-quality HIV treatment more affordable, particularly in resource-limited settings where HIV burden is highest.

Quality Assurance:
WHO prequalification of Dolutegravir products ensures quality standards are met, giving confidence to procurement programs worldwide.